Company
BrainStorm Cell Therapeutics Inc.
NASDAQ:BCLI
BrainStorm is a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases.
3 stories
Maxim Group says BrainStorm Cell Therapeutics now has sufficient cash to fund key phase 3 trial of NurOwn
NurOwn has been administered to 75 patients with amyotrophic lateral sclerosis (ALS) in clinical trials in the U.S and Israel